You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Vistusertib

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Meningioma Trial in Chicago, Boston (AZD2014)

Active, not recruiting
  • Meningioma
  • Chicago, Illinois
  • +2 more
Oct 15, 2022

Metastatic Malignant Solid Tumor, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Tumor Trial in United States

Terminated
  • Metastatic Malignant Solid Neoplasm
  • +8 more
  • Navitoclax
  • Vistusertib
  • Los Angeles, California
  • +13 more
Oct 7, 2022

DLBCL, Richter Syndrome Trial in United Kingdom, United States (acalabrutinib, vistusertib)

Terminated
Has Results
  • DLBCL
  • Richter Syndrome
  • Fairway, Kansas
  • +10 more
Jan 4, 2021

Muscle Invasive Bladder Cancer Trial in Worldwide (AZD4547, MEDI4736, Olaparib)

Active, not recruiting
  • Muscle Invasive Bladder Cancer
  • Los Angeles, California
  • +26 more
Oct 17, 2022

DLBCL Trial in United Kingdom (AZD 2014, Rituximab)

Completed
  • Diffuse Large B-Cell Lymphoma
  • Aberdeen, United Kingdom
  • +8 more
Nov 4, 2020

NSCLC, Carcinoma, Squamous Cell, Adenocarcinoma Trial in United Kingdom (AZD4547, Vistusertib, Palbociclib)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Aberdeen, United Kingdom
  • +24 more
Nov 2, 2021

Solid Tumor Trial in Seoul (Vistusertib(AZD2014))

Withdrawn
  • Solid Tumor
  • Seoul, Korea, Republic of
    Samsung Medical Center
May 17, 2019

Solid Tumor Trial in Seoul (Vistusertib(AZD2014))

Withdrawn
  • Solid Tumor
  • Seoul, Korea, Republic of
    Samsung Medical Center
May 17, 2019

Small Cell Lung Cancer Trial in Seoul (vistusertib (AZD2014))

Terminated
  • Small Cell Lung Cancer
  • vistusertib (AZD2014)
  • Seoul, Korea, Republic of
    Samsung Medical center
Sep 18, 2018

Glioblastoma Multiforme Trial in Canada (AZD2014)

Completed
  • Glioblastoma Multiforme
  • Calgary, Alberta, Canada
  • +3 more
Apr 7, 2020

Estrogen Receptor Positive Breast Cancer Trial in Worldwide (AZD2014, Everolimus, Fulvestrant)

Unknown status
  • Estrogen Receptor Positive Breast Cancer
  • Angers, France
  • +78 more
Feb 24, 2020

Core: Relapsed or Refractory DLBCL, Module 1: Non-GCB DLBCL Trial (AZD2014, Ibrutinib)

Withdrawn
  • Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
  • (no location specified)
Sep 14, 2016